R2GE34 Stock Overview
Develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Repligen Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.50 |
| 52 Week High | US$28.50 |
| 52 Week Low | US$28.50 |
| Beta | 1.03 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -19.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| R2GE34 | BR Life Sciences | BR Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how R2GE34 performed against the BR Life Sciences industry.
Return vs Market: Insufficient data to determine how R2GE34 performed against the BR Market.
Price Volatility
| R2GE34 volatility | |
|---|---|
| R2GE34 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in BR Market | 0% |
| 10% least volatile stocks in BR Market | 0% |
Stable Share Price: R2GE34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine R2GE34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 1,783 | Tony Hunt | www.repligen.com |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.
Repligen Corporation Fundamentals Summary
| R2GE34 fundamental statistics | |
|---|---|
| Market cap | R$51.98b |
| Earnings (TTM) | R$210.68m |
| Revenue (TTM) | R$3.24b |
246.7x
P/E Ratio16.1x
P/S RatioIs R2GE34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R2GE34 income statement (TTM) | |
|---|---|
| Revenue | US$638.76m |
| Cost of Revenue | US$323.54m |
| Gross Profit | US$315.23m |
| Other Expenses | US$273.65m |
| Earnings | US$41.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 49.35% |
| Net Profit Margin | 6.51% |
| Debt/Equity Ratio | 29.4% |
How did R2GE34 perform over the long term?
See historical performance and comparison